[
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD) Presents at UBS Global Healthcare Conference 2025 Transcript",
    "summary": "Gilead Sciences, Inc. (GILD) UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM ESTCompany ParticipantsAndrew Dickinson - Chief Financial...",
    "url": "https://finnhub.io/api/news?id=809bc39034834306b88af2c4bfe303419c2638b6c60aacf39c2145a9abe9962a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762785694,
      "headline": "Gilead Sciences, Inc. (GILD) Presents at UBS Global Healthcare Conference 2025 Transcript",
      "id": 137400096,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Gilead Sciences, Inc. (GILD) UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM ESTCompany ParticipantsAndrew Dickinson - Chief Financial...",
      "url": "https://finnhub.io/api/news?id=809bc39034834306b88af2c4bfe303419c2638b6c60aacf39c2145a9abe9962a"
    }
  },
  {
    "ts": null,
    "headline": "Compugen Reports Third Quarter 2025 Results",
    "summary": "Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today reported financial results for the third quarter of 2025 and provided a corporate update.",
    "url": "https://finnhub.io/api/news?id=69fdf283732ea121fa26964d2191072cf488ca8171cd38024697d96529cee246",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762776000,
      "headline": "Compugen Reports Third Quarter 2025 Results",
      "id": 137395021,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today reported financial results for the third quarter of 2025 and provided a corporate update.",
      "url": "https://finnhub.io/api/news?id=69fdf283732ea121fa26964d2191072cf488ca8171cd38024697d96529cee246"
    }
  },
  {
    "ts": null,
    "headline": "AHF’s Mobile Billboard Calls Out Gilead’s Greed at Pharma Summit",
    "summary": "LOS ANGELES, November 10, 2025--As the pharmaceutical industry gathers for the Global Pharma & Biotech Summit in London this week, AIDS Healthcare Foundation (AHF) is launching a mobile billboard that will circle the venue (Convene 22 Bishopsgate) on Nov. 11-12 to spotlight Gilead Sciences’ greed and refusal to make its breakthrough HIV prevention drug lenacapavir truly affordable and accessible.",
    "url": "https://finnhub.io/api/news?id=53b37eba6f7893eaf708bcff453e9af2dee8a9f80b7f630a947532bb3b946508",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762765200,
      "headline": "AHF’s Mobile Billboard Calls Out Gilead’s Greed at Pharma Summit",
      "id": 137395022,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "LOS ANGELES, November 10, 2025--As the pharmaceutical industry gathers for the Global Pharma & Biotech Summit in London this week, AIDS Healthcare Foundation (AHF) is launching a mobile billboard that will circle the venue (Convene 22 Bishopsgate) on Nov. 11-12 to spotlight Gilead Sciences’ greed and refusal to make its breakthrough HIV prevention drug lenacapavir truly affordable and accessible.",
      "url": "https://finnhub.io/api/news?id=53b37eba6f7893eaf708bcff453e9af2dee8a9f80b7f630a947532bb3b946508"
    }
  }
]